JAK inhibitor for severe skin rash from immunotherapy
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a JAK inhibitor pill for people with severe skin rashes caused by immunotherapy drugs like Keytruda or Opdivo. It aims to help control the rash and allow you to keep benefiting from your cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with a confirmed solid tumor cancer.
- You have had treatment with an immunotherapy drug (like Keytruda, Opdivo, or Yervoy).
- You have a severe skin rash (grade 3 or 4) from that immunotherapy.
- You have not yet received steroids for the rash, or the rash did not get better with steroids.
- Your blood counts and liver function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a JAK inhibitor (a type of drug) can help patients with solid cancers who developed severe skin rashes from immunotherapy drugs and didn't get better with steroids. The goal is to find a new treatment option for this painful side effect.
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
This trial tests a combination of two medications—guselkumab and a JAK inhibitor—for people with inflammatory bowel disease that hasn't responded to other treatments. The goal is to see if this combination is safe and effective for patients with hard-to-control Crohn's disease or ulcerative colitis.
This trial tests a combination of a steroid (methylprednisolone) and a JAK inhibitor to treat toxic epidermal necrolysis, a severe skin reaction. The goal is to see if adding the JAK inhibitor helps improve outcomes and safety.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hear when a new Immune Checkpoint Inhibitors (ICI)-Related Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.